leadf
logo-loader
viewImmuPharma PLC

Immupharma PLC - Total Share Capital Notification

RNS Number : 5041A
Immupharma PLC
30 September 2020
 

RNS | eCorporate                                                                                                                                 30 September 2020

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Total Share Capital Notification

Admission to trading on Euronext Growth Brussels of newly issued ordinary shares

 

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company's Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting rights are set out below:

 

Situation as at 30 September 2020

 

 

 

1. Information to be provided for on the basis of Article 15, §1, al. 1

 

 

 

Total of share capital (nominal value)

:

£ 24,628,580

 

 

 

Total number of shares with existing voting rights (= denominator) - one vote per share

:

246,285,805

 

 

 

2. Additional information to be provided on the basis of Article 15, §1, al. 2

 

In respect to the announcement on 11 June 2020: "Investment from two specialist US healthcare investors"

 

 

 

 

 

Convertible Securities (in whole or in part) into ordinary shares currently outstanding.

The total conversion would result in an equal number of voting rights

:

10,734,166

 

 

 

Share options (in whole or in part)

The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights.

 

:

15,703,942

In respect to the announcements on 30 March 2020: "Subscription to raise £1.5m" and 2 September 2020 "Placing to raise £6.5m"

 

 

 

 

 

Warrants over ordinary shares (in whole or in part)

The exercise of the warrants would result in the creation of an equal number of ordinary shares and voting rights

:

3,343,045

 

 

 

Other outstanding rights to subscribe ordinary shares as detailed in the Annual Report 2019 (Report and consolidated financial Statements for the year ended 31 December 2019)

 

 

 

 

 

Share options (in whole  or in part)

The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights

:

16,368,850

 

 

 

 

This situation (the denominator) serves as a basis for the notification of major holdings by shareholders.

 

Admission to trading on Euronext Growth Brussels of newly issued ordinary shares

 

As mentioned in announcements of 2, 3, 9 and 10 September 2020, ImmuPharma has issued in total 63,274,885 new ordinary shares that will be admitted to trading on Euronext Growth Brussels on 30 September 2020. An Information Note related to this admission to trading is available on www.immupharma.co.uk.   

 

 

For further information please contact:

 

ImmuPharma PLC

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

 

Degroof Petercam (Liquidity Provider)

Erik De Clippel

 

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60

 

 

+32 (0) 2 287 95 34

 

 

 

+32 (0) 477 504 784

+32 (0) 475 903 909

 

 

 

 

 

 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk 

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRMZGZLRLVGGZM

Quick facts: ImmuPharma PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3...

Dr Tim Franklin, Chief Operating Officer of ImmuPharma PLC (LON:IMM) joins Proactive London's Katie Pilbeam to discuss ImmuPharma's announcement that The US Food & Drug Administration (“FDA”) has confirmed 4th December 2020 will be the date for the Type ‘A’ Meeting Request, with Avion...

1 week, 2 days ago

6 min read